Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions

Meng Dong, Hongtao Luo, Ruifeng Liu, Jinhua Zhang, Zhen Yang, Dandan Wang, Yuhang Wang, Junru Chen, Yuhong Ou, Qiuning Zhang, Xiaohu WangJournal of Cancer 2023 · DOI

TL;DR

This study investigates combining the PARP inhibitor olaparib with radiation therapy (X-rays or carbon ions) to improve treatment outcomes for osteosarcoma, a bone cancer known for its radiation resistance. The research demonstrates that this combination significantly enhances the effectiveness of radiation by increasing cell death, inducing cell cycle arrest, and impairing DNA repair mechanisms in osteosarcoma cells, suggesting a promising new therapeutic strategy.

What Problem Does This Paper Address?

Osteosarcoma, a common bone cancer, is notoriously difficult to treat with conventional radiation therapy. This resistance stems from the cancer cells' inherent ability to repair DNA damage caused by radiation. While advanced radiation techniques like carbon ion therapy offer some improvements, local recurrence and distant metastasis remain significant challenges. The paper addresses the critical need for effective radiosensitizers – agents that make cancer cells more susceptible to radiation – to improve local control and overall treatment efficacy for osteosarcoma. Specifically, it explores the potential of olaparib, a PARP inhibitor, to overcome this radiation resistance.

Methods

The researchers employed a multi-pronged approach to assess the radiosensitizing effects of olaparib:

  • Cell Proliferation and Colony Formation Assays (CCK-8 and Clone Formation): These standard assays were used to measure how olaparib and radiation, alone and in combination, affected the ability of osteosarcoma cells (U2OS and K7M2 cell lines) to grow and form colonies.
  • Flow Cytometry: This technique was used to analyze the cell cycle distribution and apoptosis (programmed cell death) in cells treated with olaparib and/or radiation.
  • Immunofluorescence Microscopy: This method allowed visualization and quantification of DNA damage markers like γ-H2AX and 53BP1, as well as the DNA repair protein Rad51, by counting the "foci" (localized accumulations) in the cell nuclei.
  • Western Blot Analysis: This technique was used to confirm and quantify the protein expression levels of γ-H2AX, 53BP1, and Rad51.
  • Exome Gene Sequencing: This was performed to genetically characterize the U2OS and K7M2 cell lines, particularly focusing on mutations in DNA repair genes, as these can influence sensitivity to PARP inhibitors.
  • Gene Set Enrichment Analysis (GSEA): This bioinformatics approach was used to explore the signaling pathways affected by PARP inhibition.

Datasets

The study utilized two established human osteosarcoma cell lines:

  • U2OS: A human osteosarcoma cell line.
  • K7M2: A murine osteosarcoma cell line.

These cell lines were used for all experimental assays. The paper also mentions the use of a "TARGET database" for gene expression analysis in the context of osteosarcoma, but specific details about this dataset are not elaborated upon for the experimental work.

Key Insights and Ideas

  • BRCAness and PARP Inhibition Synergy: The study leverages the known sensitivity of tumors with DNA repair deficiencies (like BRCA mutations, often referred to as "BRCAness") to PARP inhibitors. By identifying that osteosarcoma cell lines possess mutations in DNA repair genes, the researchers hypothesized a synergistic effect with olaparib.
  • Dual Attack on DNA Damage: Olaparib, by inhibiting PARP, prevents the repair of single-strand DNA breaks. When combined with radiation (which causes both single and double-strand breaks), this leads to an overwhelming accumulation of unrepaired DNA damage, pushing cells towards death.
  • Impaired DNA Repair Machinery: The combination therapy not only increased DNA damage markers (γ-H2AX, 53BP1) but also significantly reduced the levels and activity of Rad51, a key protein in homologous recombination repair. This suggests olaparib actively hinders the cell's ability to fix radiation-induced double-strand breaks.
  • Carbon Ions vs. X-rays: The study explored both X-rays and carbon ions. While both radiation types showed enhanced efficacy with olaparib, the data suggests carbon ions, with their higher linear energy transfer (LET), might offer a more potent platform for this combination therapy.

Key Results

  • Reduced Proliferation and Colony Formation: Olaparib significantly reduced the proliferation and colony-forming ability of osteosarcoma cells when combined with either X-rays or carbon ions, even at the same radiation doses.
  • Enhanced Apoptosis and Cell Cycle Arrest: The combination therapy led to a significant increase in apoptosis (cell death) and G2/M phase cell cycle arrest compared to radiation alone.
  • Increased DNA Damage Markers: Immunofluorescence showed a significant increase in γ-H2AX and 53BP1 foci (markers of DNA damage) in cells treated with olaparib and radiation.
  • Inhibition of DNA Repair: The number of Rad51 foci and the expression of Rad51 protein were significantly decreased in the combination group, indicating impaired homologous recombination repair.
  • Radiosensitization Effect: The study calculated enhancement ratios (ER) for olaparib's effect on cell survival, showing that olaparib made osteosarcoma cells more sensitive to both X-rays and C-ions. The ER for C-ions was generally higher than for X-rays.

Limitations and Future Work

  • In Vitro Study: The findings are based on experiments conducted in vitro using cell lines. While promising, these results need to be validated in in vivo models (animal studies) and ultimately in clinical trials to confirm their efficacy and safety in patients.
  • Genetic Heterogeneity: The study focused on two specific cell lines (U2OS and K7M2) which were found to have mutations in DNA repair genes. Osteosarcomas exhibit significant genetic heterogeneity, and the response to olaparib might vary in tumors with different genetic profiles.
  • Clinical Application Basis: The authors conclude that their findings provide a "potential theoretical basis" for clinical application. This implies that further research is needed to determine optimal dosing, scheduling, and patient selection criteria for combining olaparib with radiotherapy in osteosarcoma patients. Future work should focus on translating these in vitro findings into clinical practice.

Summary updated

Abstract

<b>Objective:</b> Osteosarcomas are derived from bone-forming mesenchymal cells that are insensitive to radiation. This study aimed to investigate the radiosensitization of osteosarcoma cells (U2OS and K7M2) using the PARP inhibitor olaparib combined with X-rays or carbon ions (C-ions). <b>Methods:</b> The effect of olaparib on the proliferation of osteosarcoma cells after irradiation was assessed using CCK-8 and clone formation assays. Cells were treated with olaparib and/or radiation and the effects of olaparib on the cell cycle and apoptosis were analysed by flow cytometry after 48h. Immunofluorescence was used to stain the nuclei, γ-H2AX, 53BP1, and Rad51 proteins, and the number of γ-H2AX, 53BP1, and Rad51 foci was observed under a fluorescence microscope. The effect of olaparib combined with radiation on double-stranded DNA breaks in osteosarcoma cells was evaluated. <b>Results:</b> At the same radiation dose, olaparib reduced the proliferation and colony formation ability of irradiated osteosarcoma cells (P < 0.05). Olaparib monotherapy induced minimal apoptotic effects and G<sub>2</sub>/M phase arrest in osteosarcoma cells and irradiation alone induced moderate apoptosis and G<sub>2</sub>/M phase arrest. However, radiation combined with olaparib significantly increased the percentage of apoptotic cells and G2/M phase arrest in osteosarcoma cells (P < 0.05). Immunofluorescence experiments showed that compared to the radiation group, the formation of γ-H2AX and 53BP1 foci was significantly increased in the combined group (P < 0.05). The expression levels of Rad51 foci in the irradiated group were higher than those in the control group (P < 0.05). However, the number of Rad51 foci in the combined group was significantly decreased (P < 0.05). <b>Conclusion:</b> The PARP inhibitor olaparib combined with irradiation (X-rays or C-ions) enhanced the radiosensitivity of osteosarcoma cell lines (U2OS and K7M2). Our findings provide a potential theoretical basis for the clinical application of olaparib in overcoming radiation resistance in osteosarcoma.
BibTeX
@article{dong2023radiosensitization,
  author = {Meng Dong and Hongtao Luo and Ruifeng Liu and Jinhua Zhang and Zhen Yang and Dandan Wang and Yuhang Wang and Junru Chen and Yuhong Ou and Qiuning Zhang and Xiaohu Wang},
  title = {{Radiosensitization of Osteosarcoma Cells Using the PARP Inhibitor Olaparib Combined with X-rays or Carbon Ions}},
  journal = {Journal of Cancer},
  year = {2023},
  doi = {10.7150/jca.90371},
}
Figure